A Phase 2/3 interventional study of OPC-34712 and OPC-34712 in Schizophrenia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-10-03.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 6th largest by enrollment, is one of 7 that started in 2011, is the only one in phase 2/3, and was the 9th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 459 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 21st largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2011, is one of 4 in phase 2/3, and was the 43rd registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-34712
Drug: OPC-34712
Drug: OPC-34712
Drug: Placebo
Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.
PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness (CGI-S)
Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.
The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
| Milestone | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo |
|---|---|---|---|---|
| Started | 115 | 115 | 113 | 116 |
| Completed | 72 | 81 | 68 | 70 |
| Not completed | 43 | 34 | 45 | 46 |
| Withdrew: Adverse event | 19 | 12 | 18 | 21 |
| Withdrew: Withdrawal criteria | 1 | 1 | 1 | 1 |
| Withdrew: Physician decision | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 14 | 11 | 16 | 17 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 7 | 9 | 9 | 7 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| units on a scale | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo |
|---|---|---|---|---|
| Week1 | -2.68 ± 1.04 | -4.59 ± 1.03 | -3.42 ± 1.05 | -3.09 ± 1.03 |
| Week2 | -5.07 ± 1.36 | -7.93 ± 1.33 | -6.80 ± 1.36 | -4.54 ± 1.34 |
| Week3 | -6.92 ± 1.60 | -11.00 ± 1.55 | -9.42 ± 1.59 | -6.00 ± 1.58 |
| Week4 | -8.40 ± 1.81 | -12.35 ± 1.74 | -11.21 ± 1.80 | -5.67 ± 1.80 |
| Week5 | -8.13 ± 2.02 | -13.97 ± 1.93 | -11.09 ± 2.01 | -6.62 ± 2.03 |
| Week6 | -8.26 ± 2.10 | -14.95 ± 2.00 | -11.49 ± 2.10 | -7.63 ± 2.11 |
PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| units on a scale | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo |
|---|---|---|---|---|
| Week1 | -0.96 ± 0.36 | -1.31 ± 0.36 | -0.70 ± 0.36 | -1.09 ± 0.35 |
| Week2 | -1.72 ± 0.45 | -2.31 ± 0.44 | -1.61 ± 0.45 | -2.25 ± 0.44 |
| Week3 | -2.07 ± 0.52 | -3.21 ± 0.51 | -2.71 ± 0.52 | -2.57 ± 0.52 |
| Week4 | -2.39 ± 0.57 | -3.69 ± 0.54 | -3.09 ± 0.56 | -2.90 ± 0.56 |
| Week5 | -2.19 ± 0.62 | -4.05 ± 0.60 | -2.89 ± 0.62 | -3.26 ± 0.63 |
| Week6 | -2.22 ± 0.64 | -4.32 ± 0.61 | -3.15 ± 0.64 | -3.69 ± 0.64 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| units on a scale | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo |
|---|---|---|---|---|
| Week1 | -0.54 ± 0.27 | -0.83 ± 0.27 | -0.71 ± 0.27 | -0.59 ± 0.27 |
| Week2 | -1.08 ± 0.37 | -1.46 ± 0.36 | -1.76 ± 0.36 | -0.72 ± 0.36 |
| Week3 | -1.64 ± 0.41 | -2.41 ± 0.39 | -2.27 ± 0.40 | -1.14 ± 0.40 |
| Week4 | -2.36 ± 0.46 | -2.90 ± 0.44 | -2.94 ± 0.46 | -0.81 ± 0.46 |
| Week5 | -2.31 ± 0.52 | -3.24 ± 0.50 | -3.19 ± 0.52 | -0.85 ± 0.52 |
| Week6 | -2.34 ± 0.55 | -3.48 ± 0.52 | -3.24 ± 0.55 | -1.20 ± 0.55 |
Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| units on a scale | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo |
|---|---|---|---|---|
| Week1 | -0.13 ± 0.06 | -0.18 ± 0.06 | -0.09 ± 0.06 | -0.15 ± 0.06 |
| Week2 | -0.26 ± 0.08 | -0.36 ± 0.08 | -0.34 ± 0.08 | -0.25 ± 0.08 |
| Week3 | -0.38 ± 0.09 | -0.52 ± 0.09 | -0.50 ± 0.09 | -0.36 ± 0.09 |
| Week4 | -0.48 ± 0.09 | -0.62 ± 0.09 | -0.50 ± 0.09 | -0.40 ± 0.09 |
| Week5 | -0.45 ± 0.11 | -0.81 ± 0.10 | -0.56 ± 0.10 | -0.52 ± 0.11 |
| Week6 | -0.52 ± 0.11 | -0.85 ± 0.11 | -0.62 ± 0.11 | -0.57 ± 0.11 |
The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| units on a scale | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo |
|---|---|---|---|---|
| Week1 | 3.87 ± 0.92 | 3.84 ± 0.96 | 4.01 ± 0.93 | 3.92 ± 1.04 |
| Week2 | 3.87 ± 1.10 | 3.68 ± 1.02 | 3.79 ± 1.13 | 3.88 ± 1.26 |
| Week3 | 3.89 ± 1.20 | 3.53 ± 1.04 | 3.77 ± 1.20 | 3.92 ± 1.36 |
| Week4 | 3.83 ± 1.23 | 3.51 ± 1.16 | 3.81 ± 1.23 | 3.90 ± 1.36 |
| Week5 | 3.92 ± 1.27 | 3.42 ± 1.23 | 3.76 ± 1.30 | 3.86 ± 1.48 |
| Week6 | 3.90 ± 1.32 | 3.49 ± 1.30 | 3.78 ± 1.33 | 3.83 ± 1.49 |
Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 30 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 1mg | 0/115 (0%) | 8/115 (7%) | 49/115 (42.6%) |
| Brexpiprazole 2mg | 0/114 (0%) | 5/114 (4.4%) | 46/114 (40.4%) |
| Brexpiprazole 4mg | 0/113 (0%) | 5/113 (4.4%) | 49/113 (43.4%) |
| Placebo | 0/116 (0%) | 5/116 (4.3%) | 56/116 (48.3%) |
| Event | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 7/115 | 5/114 | 4/113 | 5/116 |
| AsphyxiaRespiratory, thoracic and mediastinal disorders | 0/115 | 0/114 | 1/113 | 0/116 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/115 | 1/114 | 0/113 | 0/116 |
| EosinophiliaBlood and lymphatic system disorders | 1/115 | 0/114 | 0/113 | 0/116 |
| Blood creatine phosphokinase increasedInvestigations | 1/115 | 0/114 | 0/113 | 0/116 |
| Electroencephalogram abnormalInvestigations | 1/115 | 0/114 | 0/113 | 0/116 |
| Psychiatric symptomPsychiatric disorders | 1/115 | 0/114 | 0/113 | 0/116 |
| Event | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 20/115 | 13/114 | 23/113 | 28/116 |
| NasopharyngitisInfections and infestations | 12/115 | 8/114 | 10/113 | 11/116 |
| HeadacheNervous system disorders | 8/115 | 9/114 | 3/113 | 5/116 |
| ConstipationGastrointestinal disorders | 8/115 | 8/114 | 7/113 | 9/116 |
| VomitingGastrointestinal disorders | 7/115 | 5/114 | 8/113 | 4/116 |
| AkathisiaNervous system disorders | 2/115 | 4/114 | 6/113 | 8/116 |
| Blood prolactin increasedInvestigations | 1/115 | 3/114 | 7/113 | 3/116 |
| DiarrhoeaGastrointestinal disorders | 4/115 | 3/114 | 6/113 | 2/116 |
| NauseaGastrointestinal disorders | 4/115 | 6/114 | 3/113 | 2/116 |
| Dental cariesGastrointestinal disorders | 6/115 | 0/114 | 4/113 | 1/116 |
| Age, Categorical(Participants) | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 115 | 115 | 113 | 116 | 459 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 44.7 ± 11.5 | 43.3 ± 12.0 | 44.1 ± 11.9 | 45.0 ± 11.9 | 44.3 ± 11.8 |
| Sex: Female, Male(Participants) | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 64 | 54 | 58 | 65 | 241 |
| Male | 51 | 61 | 55 | 51 | 218 |
| Region of Enrollment(participants) | Brexpiprazole 1mg | Brexpiprazole 2mg | Brexpiprazole 4mg | Placebo | Total |
|---|---|---|---|---|---|
| Japan | 115 | 115 | 113 | 116 | 459 |
The record gives a start of Oct 2011 and a primary completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Co., Ltd. →